title: Comparison of the effects of the GABAB receptor positive modulator BHF177 and the GABAB receptor agonist baclofen on anxiety-like behavior, learning, and memory in mice.
abstract: γ-Aminobutyric acid B (GABAB) receptor activation is a potential therapeutic approach for the treatment of drug addiction, pain, anxiety, and depression. However, full agonists of this receptor induce side-effects, such as sedation, muscle relaxation, tolerance, and cognitive disruption. Positive allosteric modulators (PAMs) of the GABAB receptor may have similar therapeutic effects as agonists with superior side-effect profiles. The present study behaviorally characterized N-([1R,2R,4S]-bicyclo[2.2.1]hept-2-yl)-2-methyl-5-(4-[trifluoromethyl]phenyl)-4-pyrimidinamine (BHF177), a GABAB receptor PAM, in mouse models of anxiety-like behavior, learning and memory. In addition, the effects of BHF177 were compared with the agonist baclofen. Unlike the anxiolytic chlordiazepoxide, baclofen (0.5, 1.5, and 2.5 mg/kg, intraperitoneally) and BHF177 (10, 20, and 40 mg/kg, orally) had no effect on anxiety-like behavior in the elevated plus maze, light/dark box, or Vogel conflict test. Baclofen increased punished drinking in the Vogel conflict test, but this effect may be attributable to the analgesic actions of baclofen. At the highest dose tested (2.5 mg/kg), baclofen-treated mice exhibited sedation-like effects (i.e., reduced locomotor activity) across many of the tests, whereas BHF177-treated mice exhibited no sedation-like effects. BHF177 exhibited pro-convulsion properties only in mice, but not in rats, indicating that this effect may be species-specific. At doses that were not sedative or pro-convulsant, baclofen and BHF177 had no selective effects on fear memory retrieval in contextual and cued fear conditioning or spatial learning and memory in the Barnes maze. These data suggest that BHF177 has little sedative activity, no anxiolytic-like profile, and minimal impairment of learning and memory in mice.
authors: Department of Psychiatry, School of Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0603, USA.
authors: Xia
authors: X
authors: Li
authors: Victoria B
authors: VB
authors: Risbrough
authors: Chelsea
authors: C
authors: Cates-Gatto
authors: Katarzyna
authors: K
authors: Kaczanowska
authors: M G
authors: MG
authors: Finn
authors: Amanda J
authors: AJ
authors: Roberts
authors: Athina
authors: A
authors: Markou
mesh_terms: D000818:Animals; D001007:Anxiety / Q000188:drug therapy*; D001418:Baclofen / Q000494:pharmacology*; D002707:Chlordiazepoxide / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D058786:GABA-B Receptor Agonists / Q000494:pharmacology*; D008297:Male; D018782:Maze Learning / Q000187:drug effects*; D008568:Memory / Q000187:drug effects*; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D009636:Norbornanes / Q000138:chemical synthesis / Q000494:pharmacology*; D010433:Pentylenetetrazole; D011743:Pyrimidines / Q000138:chemical synthesis / Q000494:pharmacology*; D051381:Rats; D012640:Seizures / Q000139:chemically induced / Q000188:drug therapy
chemical_list: D058786:GABA-B Receptor Agonists; C560183:N-(bicyclo(2.2.1)hept-2-yl)-2-methyl-5-(4-(trifluoromethyl)phenyl)-4-pyrimidinamine; D009636:Norbornanes; D011743:Pyrimidines; D002707:Chlordiazepoxide; D001418:Baclofen; D010433:Pentylenetetrazole
references: Eur J Pharmacol. 1997 Aug 13;332(3):245-55
references: 9300256
references: Pharmacol Rep. 2007 Nov-Dec;59(6):757-62
references: 18195467
references: Adv Pharmacol. 2010;58:315-71
references: 20655488
references: Br J Pharmacol. 2011 Oct;164(4):1129-61
references: 21545412
references: Pharmacol Biochem Behav. 2001 May-Jun;69(1-2):9-15
references: 11420063
references: Eur J Pharmacol. 2003 Feb 28;463(1-3):67-96
references: 12600703
references: Front Behav Neurosci. 2011 Jul 22;5:40
references: 21811448
references: Nat Rev Drug Discov. 2002 Mar;1(3):198-210
references: 12120504
references: Pharmacol Toxicol. 1993 Mar;72(3):159-62
references: 8390652
references: Eur J Pharm Sci. 2004 Mar;21(4):407-20
references: 14998571
references: Drug Alcohol Depend. 2002 Feb 1;65(3):209-20
references: 11841892
references: J Med Chem. 2008 Nov 13;51(21):6866-75
references: 18921991
references: Neuropsychopharmacology. 2007 Feb;32(2):388-98
references: 16710312
references: Behav Brain Res. 2010 Mar 17;208(1):258-64
references: 20006648
references: Prog Neurobiol. 1991;36(1):35-92
references: 1847747
references: Behav Pharmacol. 2000 Sep;11(6):495-504
references: 11103915
references: Psychopharmacology (Berl). 1996 Dec;128(4):380-97
references: 8986009
references: Trends Pharmacol Sci. 2005 Jan;26(1):36-43
references: 15629203
references: Prog Neurobiol. 2003 Jun;70(2):83-244
references: 12927745
references: Br J Pharmacol. 1975 Jun;54(2):171-9
references: 1148507
references: Pharmacol Rep. 2007 Nov-Dec;59(6):645-55
references: 18195453
references: Neuropharmacology. 1985 Mar;24(3):211-6
references: 2986037
references: Psychopharmacology (Berl). 2007 Aug;193(2):171-8
references: 17393141
references: Life Sci. 2010 Oct 23;87(17-18):521-36
references: 20837032
references: Acta Neurobiol Exp (Wars). 2010;70(1):56-66
references: 20407487
references: Eur J Pharmacol. 1993 Apr 22;235(1):109-12
references: 8519271
references: Bioorg Med Chem Lett. 2007 Nov 15;17(22):6206-11
references: 17884493
references: Pharmacol Biochem Behav. 1992 Mar;41(3):651-3
references: 1316620
references: J Pharmacol Exp Ther. 2011 Sep;338(3):897-905
references: 21636656
references: Brain Res. 1997 Aug 22;766(1-2):101-6
references: 9359592
references: Curr Top Behav Neurosci. 2010;2:121-60
references: 21309109
references: Behav Neural Biol. 1989 Sep;52(2):170-9
references: 2552976
references: Psychopharmacology (Berl). 1993;111(2):134-8
references: 7870943
references: Neuropsychopharmacology. 2004 Jun;29(6):1050-62
references: 15039762
references: Life Sci. 1988;42(8):933-42
references: 2893966
references: Psychopharmacology (Berl). 2011 May;215(1):117-28
references: 21181127
references: Trends Pharmacol Sci. 1989 Oct;10(10):401-7
references: 2559518
references: Annu Rev Pharmacol Toxicol. 1978;18:269-89
references: 25608
references: Eur J Pharmacol. 2001 Aug 24;426(1-2):45-54
references: 11525770
references: Behav Brain Res. 2009 Mar 2;198(1):247-51
references: 18996418
references: Ann N Y Acad Sci. 2000;909:170-85
references: 10911930
references: Pharmacol Res. 2002 Sep;46(3):281-6
references: 12220972
references: Nature. 1998 Dec 17;396(6712):683-7
references: 9872317
references: J Pharmacol Exp Ther. 2004 Sep;310(3):952-63
references: 15113848
references: Adv Pharmacol. 2010;58:427-51
references: 20655491
references: Neuropharmacology. 2008 Apr;54(5):854-62
references: 18328507
references: Rep US Army Med Res Lab. 1961 May 22;476:1-9
references: 13697611
references: CNS Drug Rev. 2005 Autumn;11(3):317-34
references: 16389296
references: Jpn J Pharmacol. 1999 Jun;80(2):111-8
references: 10440529
references: Pharmacol Biochem Behav. 1996 May;54(1):21-30
references: 8728535
references: Naunyn Schmiedebergs Arch Pharmacol. 1991 Sep;344(3):314-22
references: 1660103
references: Br J Pharmacol. 1983 Apr;78(4):701-8
references: 6850167
references: Nature. 1998 Dec 17;396(6712):674-9
references: 9872315
references: Pharmacol Ther. 2006 Jun;110(3):533-43
references: 16644017
references: Alcohol Clin Exp Res. 2008 Sep;32(9):1558-64
references: 18616673
references: Neuropeptides. 1988 Oct;12(3):155-8
references: 3241628
references: Biochem Pharmacol. 2004 Oct 15;68(8):1477-8
references: 15451389
references: Neuroscience. 2003;118(4):1121-7
references: 12732255
references: Behav Brain Res. 2010 Sep 1;212(1):96-102
references: 20363258
references: Physiol Rev. 2004 Jul;84(3):835-67
references: 15269338
references: Behav Neural Biol. 1994 Mar;61(2):181-5
references: 8204084
references: J Pharmacol Exp Ther. 2008 Jul;326(1):306-14
references: 18445779
references: J Neural Transm Suppl. 1992;35:179-88
references: 1324979
references: Pharmacol Biochem Behav. 1996 Feb;53(2):303-8
references: 8808136
references: Psychopharmacology (Berl). 2004 Nov;176(2):166-74
references: 15064920
references: Annu Rev Neurosci. 2001;24:897-931
references: 11520922
references: Braz J Med Biol Res. 1997 Mar;30(3):289-304
references: 9246227
references: Trends Neurosci. 1988 Mar;11(3):112-6
references: 2465608
references: Curr Drug Abuse Rev. 2008 Nov;1(3):303-27
references: 19430578
references: Pharmacol Biochem Behav. 2008 Jul;90(1):37-42
references: 18457867
references: Neuron. 2006 May 18;50(4):589-601
references: 16701209
references: J Pharmacol Exp Ther. 2007 Apr;321(1):172-7
references: 17215447
references: J Biol Chem. 1999 Sep 17;274(38):27323-30
references: 10480953
references: J Pharmacol Exp Ther. 2002 Jan;300(1):2-8
references: 11752090
references: Eur J Pharmacol. 2011 Mar 25;655(1-3):52-8
references: 21262222
references: Behav Neurosci. 2003 Jun;117(3):517-25
references: 12802880
references: Psychopharmacology (Berl). 2006 Jul;186(4):504-16
references: 16758238
references: Behav Pharmacol. 2004 Jul;15(4):293-7
references: 15252280
references: Alcohol Clin Exp Res. 2009 Oct;33(10):1749-56
references: 19572981
references: J Comp Neurol. 2000 Jan 24;416(4):475-95
references: 10660879
references: Neuropsychopharmacology. 2005 Nov;30(11):2065-72
references: 15841108
references: Pharmacol Biochem Behav. 1987 Feb;26(2):463-74
references: 3033701